Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × sintilimab × Clear all
NCT05161572 2025-06-18

NeoRacing

Fudan University

Phase 2 Terminated
6 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04202601 2019-12-19

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Peking University

Phase 1/2 Unknown
80 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡